This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

20 Jan 2011

Bayer and Regeneron Start New Trial for Eye Disease Solution

Bayer HealthCare and Regeneron Pharmaceuticals have started a new Phase III clinical trial in Asia to find a cure solution for myopia.

Myopia is a prevalent eye condition in Asian countries such as Singapore and Japan, where around 40% of adults have myopia and nearly 10% of these have high myopia. A new Phase III clinical trial as a treatment study for patients with choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia has been initiated by Bayer HealthCare and Regeneron Pharmaceuticals in Japan.


In collaboration with the Singapore Eye Research Institute (SERI), the trial, named MYRROR, has a goal to investigate the efficacy and safety of VEGF Trap-Eye (aflibercept ophthalmic solution) in patients. The trial will be performed in some other Asian regions including China, Korea Singapore and Taiwan.


Myopic CNV is a complication of high myopia where abno

Related News